217 R 01 R 02 3 NHO 2010 1 2017 12 8 22 IGRA 9 13 18 56 20 15 4 12 10 IGRA 18 15 1 2 18 9 9 12 RFP 1 1 2015 7 2018 6 329 42 18 24 21 74 20 33 13 11 9 27 9 3 1 29 1 2 4 24 18 18 24 9 7 INH 8 RFP 2 1 HREZ
218 94 3 2019 3 R 03 R 04 3 10 7.9 24 13.9 4 20 30 5 4 2 2015 4 2018 3 3 12 98 110 5 3 1 5 7 6 7 7 5 7 0 5 4 10 1 1 2 T SPOT 11 1 5 2 3 1 9 4 INH SM TH 1 INH SM 1 SM KM 1 SM 1 PAS 1
219 R 05 R 06 13 1 1 1 1 1 1 2 1 2 2013 2013 5 2018 7 19 14 5 29 15 30 59 3 60 1 14 1 4 1 17 1 2 9 IGRA 6 2 1 1 1 12 2 2 3 5 2 I/II/III 0/ 6/ 13 3 3 13 1 10 1 1 2 2 1 1 DOTS 1 8 118,197 4,406 30 9 30 2012 2018 46 13 7 6 18 39 23.2 11 5 3 2 1 1 1 9 2 1 1 8 2 HRCT 12 γ IGRA Interferon Gamma release assay 11 QFT 2G 2 T SPOT 9 7 5 2 7 6 Gaffky
220 94 3 2019 3 R 07 R 08 1 1 1 1 2 1 1 2 25 1 30 10 28 14 14 20 70 31 8 7 3 2 2 2 1 1 1 1 1 9 1 5 6 5 13 742 3.8 5.5 2.9 26 20 2 2 1 1 2 Xp HIV 1 4 5 2 INH RFP EB SM INH RFP EB SM TH SM TH 1 LVFX 1 26 2 1 2016 4 2018 9 18 19 76 20 11 9 9 4 3 2 1 10 4 2 1 1 11 X 7 1 INH 2 8 7 3 1 20 12.7 DOTS
221 R 09 R 10 10 13.3 2017 782017 6 2017 5 68,028 287,727 240,548 57,481 33,486 16,102 6 5 2013 11 2018 10 140 14 10 8 2 2 6 2 3 1 2 1 1
222 94 3 2019 3 R 11 R 12 1 2 3 4 1 2 3 4 1 2 1 2 29 15 19 20 29 8.3 21.7 2.5 9.8 3.3 2.2 15 19 65.720 29 63.4 13 1 2 1 2 3 QFT 87.5 5 1 7 12 QFT 243 QFT 54 22.2 13 LTBI 32 DOTS 1 LTBI 2 6 VNTR QFT IGRA 1 1 2 3 20 64.0 491 2017 11 23 12 23 2018 1 11 1 31 2016 1 12 1 2016 1 2017 12 1 2 3 87.8431/491 89.3341/382 77.967/86 100 23/23 66.4286/431 10030/ 30 309/30 1760 540 30.7 76 1 39 51 26 88 20.3
223 R 13 RFP RFP 1 R 14 4 1 1 2 3 3 3 3 1 1 NHO 1 2 3 1 1 1 1 1 1 2 3 1 2 3 1 2 MIC RFP RFP RFP MIC 53 MDRTB RFP MIC 32RFP 1 RFP MIC 0.03 MIC MiSeq RFP rpob 176 V F RFP V176L V176L LVFX V176F gyra LVFX V176 L LVFX V176F LVFX RFP LVFX RFP 2017 52 0.5 2012 2 2018 2 4 2012 2018 6 4 1 80 HREZ INH RFP SM EB KM TH CS 6 LVFX PAS SM EB TH CS EB 3 2 2 40 6 HREZ INH RFP EB LVFX PAS SM CS PZA TH 5 SM50g 3 2 3 20 HREZ 2 INH RFP PAZ EB SM LVFX KM TH CS DEL PAS 4 20 HREZ INH RFP PAZ EB SM KM TH CS DEL LVFX 2 1 2
224 94 3 2019 3 R 15 R 16 1 1 1 1 1 1 1 2 2 2 1 2 2010 4 2018 3 28 2018 10 30 18 10 61 BMI 18.3 kg/m 2 6 5 3 3 17 20 25 22 SM 13 KM 8 TH 8 PZA 7 LVFX 7 5 3 4 LVFX 21 PZA SM 14 TH 12 DLM 9 3 12 6 2 1 6 3 3 1 20 MDR TBXDR TB 2002 2018 16 16 MDR TB 11 XDR TB 5 54.0 22 79 10 6 14 2 MDR TB 11 RFP INH EB 9 SM 9 TH 1 XDR TB 5 RFP INH LVFX EB KM 4 SM 3 PAS 1 EVM 3 10 XDR TB 3 5 3 1 4 1 2 7 9 7 2 1
225 R 17 R 18 delamanid 2013 3 2014 7 2017 multi drug resistant pulmonary tuberculo sis MDR TB 24 xtensively resistant pulmonary tuberculosis XDR TB 3 11 49.3 21 72 9 37.1 20 58 placebo QT 27 2 1 3 1 1 linezolid 1 27 10 bedaquilin 2018 7 QT 2 2016 1 LVFX LVFX LVFX LVFX 2008 2017 10 LVFX 1097 LVFX 25 2.3 12 13 71.2 2008 2017 1 4 6 4 4 1 1 2 2 0 2008 2012 5 19 76.0 18 7 I 1 II 15 III 9 1 4 2 17 3 4 15 10 40 FQs1 4 52.0 10 2007 INH 3.1RFP 0.7 SM 5.6EB 1.3 LVFX 2.3 LVFX LVFX 2 3 FQs FQs
226 94 3 2019 3 R 19 Bedaquiline Delamanid R 20 DNA 1 1 2 1 1 1 1 1 1 2,3 3 1 1 2 3 Bedaquiline BDQ Delamanid DLM /M/XDR TB BDQ Rv0678 Clofazimine CLF DLM fgd1 Rv0407 fbic Rv1173 fbib Rv3262 fbia Rv3261 ddn Rv3547 BDQ CLF DLM 1998 2016 M /XDR TB 178 Isoplant DNA QIAseq FX DNA Library Kit QiagenMiSeq illu minatgs TB BDQ CLF DLM BDQ CLF TB exist MGIT 960 Becton DickinsonDLM 7H11 BDQ MIC 178 10 5.6 Rv0678 9 BDQ 7 CLF 4 9 BDQ MIC MGIT 0.125 1μg/ ml 0.008 0.25μg/ml 0.03 0.125 μg/ml DLM 81.5fgd1 c.960t C fbic, fbia, ddn Villellas C MDR TB Rv0678 6.3 Rv0678 BDQ CLF BDQ/CLF HSP65 DNA IL 12 DNA plasmid HVJ /Hsp65 DNA+IL 12 DNA PMDA I PMDA PMDA pdna PMDA / I PMDA AMED David McMurray Texas A M Dr. Esterlina Tan, Dr. Paul Saunderson, Dr. Mar jorie Cang
227 R 21 Mycobacterium shinjukuense 1 R 22 16SrRNA gene Sequence M. shinjukuense 1 77 74 2015 9 2015 9 28 X CT Mycobacte rium shinjukuense PCR DDH Mycobacterium shinjukuense 1 1 2 3 4 5 2 3 7 6 2 1 2 3 4 5 6 7 Background DNA Se quence Materials/Methods 64 35 2011 12 ± MAC PCR DDH 2016 9 2 LAMP MAC PCR DDH 16S rrna gene Sequence Results 16Sr RNA M. shinjukuense 100 Concllusion M. shinjukuense 2011 Ruyon 3 MTD TRC CAM RFP EB INH RFP EB
228 94 3 2019 3 R 23 DNA DNA hybridization 3 R 24 Mycobacterium mageritense 4 1 1 2 1 2 1 57 X 13 CT S2 S5 X 8 X DNA DNA hybridization DDH 16SrRNA Mycobacte rium shinjukuense 2 73 X CT S3 DDH 16SrRNA rpob Mycobacterium kyorinense 3 92 X CT S3 S 6 DDH 16SrRNA rpob Mycobacterium shi gaense 3 DDH matrix assisted la ser desorption ionization time of flight mass spectrome try MALDI TOF MS MALDI TOF MS Mycobac terium avium complex Mycobacterium kansasii Runyon Mycobacterium mageritense M. mageritense 2013 2018 M. mageritense 4 1 76 M. mageritense CT 2 63 CT 3 55 CT 4 62 CT 4
229 R 25 Mycolicibac terium mageritense 1 R 26 20 Mycobacte rium simiae 1 1 1 1 1 1 1 2 2 1 1 2 65 51 X 10 NTMCAM+RFP +EB 3 2 X 8 6 3 9 DDH My colicibacterium fortuitum NTM 11 CAM+LVFX 2 2 X 6 11 X 1 7 8 12 0.5mg/kg/ X 3 29 4 10 4 19 3 MALDI Biotyper M. mageritense 16S rrna rpob M. mageritense 3 CAM+STFX STFX+MINO NTM M. simiae 80 3 60 61 M. simiae DDH 16SrRNA M. simiae CAM RFP EB 70 75 M. avium complex M. simiae 80 M. simiae 20
230 94 3 2019 3 R 27 1 R 28 Nivolumab 1 54 pt3n3m1 pstageiv 5 IGRA 10 PD PCR biii2 8 4 2 CTCAE Grade3 Grade1 5 5 3 5 4 Grade4 PCR 2 2 1 4 20 12 60 / 15 / 45 ct4n3m1a IVA PD L1 100 20XY 10 25 CBDCA+S 1 20XY+1 1 20 PD 1 24 Nivolumab NIVO PR20XY+2 1 9 25 1 23 ADA49.4IU/L 4 2 27 HREZ NIVO IGRA NIVO 3 NIVO
231 R 29 1 1 1 1 1 1 1 1 1 1 1 2 1 2 non small cell lung cancer NSCLC immune checkpoint inhibitor ICI nontuberculous mycobacteria NTM NSCLC ICI ICI NTM NSCLC 2 1 80 ex smoker X M. avium M. abscessus X+8 ct2an0m0 StageI PD L1 TPS 50 79 NTM 60Gy ICI NTM 1 2 60 ex smoker Y pt1an0m1b StageIV PD L1 TPS 1 24 M. kansasii erythromycin ICI NTM RFP+INH+EB3 ICI NTM ICI NTM PD L1 ICI